Skip to main content
COR
NYSE Life Sciences

Cencora 通过收购 EyeSouth Partners 扩大其 Retina Consultants of America 业务

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$330.5
Mkt Cap
$63.594B
52W Low
$264.33
52W High
$377.54
Market data snapshot near publication time

summarizeSummary

Cencora 宣布计划通过收购 EyeSouth Partners 的视网膜业务来扩大其 Retina Consultants of America 业务。这一战略举措旨在加强 Cencora 在专业眼科市场的存在感和能力。该收购符合 Cencora最近的增长战略,包括在其最近的 Q1 盈利报告中提到的详细的 46 亿美元 OneOncology 收购。虽然本次交易的具体财务条款没有披露,但这表明在关键的医疗保健领域继续进行非有机增长。交易者将监测该交易的财务影响和整合计划的进一步细节。

在该公告发布时,COR的交易价格为$330.50,交易所为NYSE,所属行业为Life Sciences,市值约为$635.9亿。 52周交易区间为$264.33至$377.54。 这则新闻被评估为积极市场情绪,重要性评分为7/10。 来源:Dow Jones Newswires。


show_chartPrice Chart

Share this article

Copied!

feed COR - Latest Insights

COR
Mar 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
COR
Mar 23, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
COR
Mar 17, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
COR
Feb 18, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
9
COR
Feb 10, 2026, 5:26 PM EST
Filing Type: FWP
Importance Score:
8
COR
Feb 04, 2026, 2:43 PM EST
Filing Type: 10-Q
Importance Score:
7
COR
Feb 04, 2026, 6:31 AM EST
Filing Type: 8-K
Importance Score:
8
COR
Jan 22, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
COR
Jan 16, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8